HomeAboutRankingsData Sources
Β© 2026 GeneE
🧬
GeneE
10 sources retrieved Β· Most recent: April 2026 Β· Index updated 14 days ago
β“˜GeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
CACNA1E
calcium voltage-gated channel subunit alpha1 E
Chromosome 1 Β· 1q25.3
NCBI Gene: 777Ensembl: ENSG00000198216.14HGNC: HGNC:1392UniProt: Q15878
66PubMed Papers
21Diseases
10Drugs
33Pathogenic Variants
FUNCTIONAL ROLE
Highly ConstrainedIon ChannelTransporter
CLINICAL
FDA Approved TargetOMIM Disease Gene
DATA QUALITY
βœ“ Experimental GO Evidenceβœ“ Swiss-Prot Reviewed
voltage-gated monoatomic cation channel activityvoltage-gated calcium channel activityneuronal cell bodyhigh voltage-gated calcium channel activitygenetic developmental and epileptic encephalopathySeizureepilepsyfibromyalgia
✦AI Summary

CACNA1E encodes the alpha-1E subunit of voltage-gated CaV2.3 calcium channels, which mediate R-type calcium currents essential for synaptic transmission in the central nervous system 1. The protein functions as a high voltage-activated calcium channel that conducts calcium ions into excitable cells, playing critical roles in neurotransmitter release and neuronal excitability 1. Mechanistically, CACNA1E variants cause disease primarily through gain-of-function effects, including facilitated voltage-dependent activation, slowed inactivation, and increased current density, leading to enhanced calcium influx 1. These functional alterations cluster predominantly within the cytoplasmic ends of S6 segments that form the channel activation gate 1. CACNA1E is strongly associated with developmental and epileptic encephalopathy 69, characterized by refractory infantile-onset seizures, severe hypotonia, profound developmental impairment, congenital contractures, macrocephaly, and hyperkinetic movement disorders 1. The gene has also been implicated in intellectual disability/global developmental delay, with gain-of-function variants typically associated with more severe phenotypes 2. Additionally, CACNA1E was identified as a risk locus in post-traumatic stress disorder, classified among neurotransmitter and ion channel synaptic modulators 3. Clinically, some patients achieve seizure control with topiramate, which blocks R-type calcium channels, suggesting targeted therapeutic potential 1.

Sources cited
1
CACNA1E encodes CaV2.3 channels conducting R-type calcium currents and causes developmental and epileptic encephalopathy through gain-of-function mechanisms
PMID: 30343943
2
CACNA1E variants are associated with intellectual disability/global developmental delay, with gain-of-function variants causing more severe phenotypes
PMID: 33985586
3
CACNA1E was identified as a risk locus for post-traumatic stress disorder and classified as a neurotransmitter/ion channel synaptic modulator
PMID: 38637617
⚠Limited data available β€” This gene has 3 indexed publications. Summary and analysis may be incomplete.
Disease Associationsβ“˜21
genetic developmental and epileptic encephalopathyOpen Targets
0.72Strong
SeizureOpen Targets
0.72Strong
epilepsyOpen Targets
0.61Moderate
fibromyalgiaOpen Targets
0.61Moderate
neuropathic painOpen Targets
0.60Moderate
restless legs syndromeOpen Targets
0.58Moderate
neuralgiaOpen Targets
0.58Moderate
anxiety disorderOpen Targets
0.57Moderate
postherpetic neuralgiaOpen Targets
0.57Moderate
spinal cord injuryOpen Targets
0.54Moderate
developmental and epileptic encephalopathyOpen Targets
0.50Moderate
genetic disorderOpen Targets
0.49Moderate
Focal-onset seizureOpen Targets
0.48Moderate
cardiovascular diseaseOpen Targets
0.47Moderate
Global developmental delayOpen Targets
0.46Moderate
Intellectual disabilityOpen Targets
0.46Moderate
MacrocephalyOpen Targets
0.46Moderate
DystoniaOpen Targets
0.46Moderate
lethal congenital contracture syndromeOpen Targets
0.46Moderate
mathematical abilityOpen Targets
0.46Moderate
Developmental and epileptic encephalopathy 69UniProt
Pathogenic Variants33
NM_001205293.3(CACNA1E):c.2104G>A (p.Ala702Thr)Pathogenic
Inborn genetic diseases|Developmental and epileptic encephalopathy, 69|not provided|Van der Woude syndrome 1|Developmental and epileptic encephalopathy
β˜…β˜…β˜†β˜†2025β†’ Residue 702
NM_001205293.3(CACNA1E):c.2094C>A (p.Phe698Leu)Pathogenic
not provided|Developmental and epileptic encephalopathy, 69
β˜…β˜…β˜†β˜†2025β†’ Residue 698
NM_001205293.3(CACNA1E):c.1042G>C (p.Gly348Arg)Pathogenic
Developmental and epileptic encephalopathy, 69|Developmental and epileptic encephalopathy|not provided
β˜…β˜…β˜†β˜†2025β†’ Residue 348
NM_001205293.3(CACNA1E):c.1054G>A (p.Gly352Arg)Pathogenic
not provided|Developmental and epileptic encephalopathy, 69|Inborn genetic diseases|Developmental and epileptic encephalopathy|CACNA1E-related disorder
β˜…β˜…β˜†β˜†2024β†’ Residue 352
NM_001205293.3(CACNA1E):c.1807A>C (p.Ile603Leu)Pathogenic
not provided|Developmental and epileptic encephalopathy, 69|Developmental and epileptic encephalopathy
β˜…β˜…β˜†β˜†2022β†’ Residue 603
NM_001205293.3(CACNA1E):c.683T>C (p.Leu228Pro)Pathogenic
not provided|Developmental and epileptic encephalopathy|Developmental and epileptic encephalopathy, 69
β˜…β˜…β˜†β˜†2017β†’ Residue 228
NM_001205293.3(CACNA1E):c.3655C>T (p.Arg1219Ter)Pathogenic
Inborn genetic diseases
β˜…β˜†β˜†β˜†2025β†’ Residue 1219
NM_001205293.3(CACNA1E):c.1055G>A (p.Gly352Glu)Likely pathogenic
Developmental and epileptic encephalopathy, 69
β˜…β˜†β˜†β˜†2025β†’ Residue 352
NM_001205293.3(CACNA1E):c.1714C>T (p.Arg572Ter)Pathogenic
Inborn genetic diseases
β˜…β˜†β˜†β˜†2025β†’ Residue 572
NM_001205293.3(CACNA1E):c.4736G>C (p.Arg1579Pro)Likely pathogenic
Developmental and epileptic encephalopathy, 69
β˜…β˜†β˜†β˜†2024β†’ Residue 1579
NM_001205293.3(CACNA1E):c.2105C>G (p.Ala702Gly)Likely pathogenic
Inborn genetic diseases
β˜…β˜†β˜†β˜†2024β†’ Residue 702
NM_001205293.3(CACNA1E):c.901_904del (p.Thr301fs)Likely pathogenic
Developmental and epileptic encephalopathy, 69
β˜…β˜†β˜†β˜†2024β†’ Residue 301
NM_001205293.3(CACNA1E):c.4389C>G (p.Asn1463Lys)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2024β†’ Residue 1463
NM_001205293.3(CACNA1E):c.587G>A (p.Arg196Gln)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2024β†’ Residue 196
NM_001205293.3(CACNA1E):c.1808_1812delinsGAGAA (p.Ile603_Ile604delinsArgGlu)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2024β†’ Residue 603
NM_001205293.3(CACNA1E):c.638C>G (p.Ser213Cys)Likely pathogenic
not provided
β˜…β˜†β˜†β˜†2024β†’ Residue 213
NM_001205293.3(CACNA1E):c.3697G>A (p.Ala1233Thr)Likely pathogenic
Developmental and epileptic encephalopathy, 69
β˜…β˜†β˜†β˜†2023β†’ Residue 1233
NM_001205293.3(CACNA1E):c.1090C>T (p.Arg364Ter)Likely pathogenic
Developmental and epileptic encephalopathy, 69
β˜…β˜†β˜†β˜†2023β†’ Residue 364
NM_001205293.3(CACNA1E):c.2098G>A (p.Ala700Thr)Pathogenic
Developmental and epileptic encephalopathy|not provided
β˜…β˜†β˜†β˜†2022β†’ Residue 700
NM_001205293.3(CACNA1E):c.4264A>T (p.Ile1422Phe)Pathogenic
Developmental and epileptic encephalopathy|not provided
β˜…β˜†β˜†β˜†2022β†’ Residue 1422
View on ClinVar β†—
Drug Targets10
ATAGABALINPhase II
Voltage-gated calcium channel modulator
insomnia
BEPRIDILApproved
Voltage-gated calcium channel blocker
cardiovascular disease
GABAPENTINApproved
Voltage-gated calcium channel modulator
epilepsy
GABAPENTIN ENACARBILApproved
Voltage-gated calcium channel modulator
restless legs syndrome
IMAGABALINPhase III
Voltage-gated calcium channel modulator
generalized anxiety disorder
PHLOROGLUCINOLApproved
Voltage-gated calcium channel blocker
gastrointestinal disease
PREGABALINApproved
Voltage-gated calcium channel modulator
neuropathic pain
SULOCTIDILApproved
Voltage-gated calcium channel blocker
cardiovascular disease
TERODILINEApproved
Muscarinic acetylcholine receptor antagonist
Urinary incontinence
TERODILINE HYDROCHLORIDEUNKNOWN
Muscarinic acetylcholine receptor antagonist
Related Genes
CAV3Protein interaction100%CACNA2D1Protein interaction100%CACNG4Protein interaction99%CACNA2D2Protein interaction98%CACNG7Protein interaction98%CACNA2D4Protein interaction96%
Tissue Expression6 tissues
Brain
100%
Bone Marrow
18%
Lung
1%
Heart
1%
Liver
1%
Ovary
0%
Gene Interaction Network
Click a node to explore
CACNA1ECAV3CACNA2D1CACNG4CACNA2D2CACNG7CACNA2D4
PROTEIN STRUCTURE
Preparing viewer…
PDB3BXL Β· 2.30 Γ… Β· X-ray
View on RCSB β†—
Constraintβ“˜
LOEUFβ“˜
0.22Highly Constrained
pLIβ“˜
1.00Intolerant
Observed/Expected LoF0.16 [0.12–0.22]
RankingsWhere CACNA1E stands among ~20K protein-coding genes
  • #7,045of 20,598
    Most Researched66
  • #234of 1,025
    FDA-Approved Drug Targets7 Β· top quartile
  • #1,727of 5,498
    Most Pathogenic Variants33
  • #569of 17,882
    Most Constrained (LOEUF)0.22 Β· top 5%
Genes detectedCACNA1E
Sources retrieved10 papers
Response timeβ€”
πŸ“„ Sources
10β–Ό
1
Malignant hyperthermia: a review.
PMID: 26238698
Orphanet J Rare Dis Β· 2015
1.00
2
Periodic paralysis.
PMID: 39174253
Handb Clin Neurol Β· 2024
0.90
3
Calcium channelopathies and intellectual disability: a systematic review.
PMID: 33985586
Orphanet J Rare Dis Β· 2021
0.80
4
Genome-wide association analyses identify 95 risk loci and provide insights into the neurobiology of post-traumatic stress disorder.
PMID: 38637617
Nat Genet Β· 2024
0.70
5
Genetic epidemiology of malignant hyperthermia in the UK.
PMID: 30236257
Br J Anaesth Β· 2018
0.60